About: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.03 (-2.25%)
RGNX NASDAQ Regenxbio Inc
Regenxbio Inc share price
RGNX price activity
Last Price
$8.030
Change (24hr)
-0.19 USD (-2.25%)
Volume
3.36M
Volume (4w avg)
-
Open
$8.22
Day Range
$8.00 - $8.33
Previous Close
$8.22
Last Trade
18 Sep, 8:26 pm GMT+0
Delayed
18 Sep, 8:26 pm GMT+0
RGNX price performance
Delayed
18 Sep, 8:26 pm GMT+0
RGNX Market Signals